Vertex Pharmaceuticals VRTX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| ALYFTREK | $424.4M+11.7% | $380.1M+53.9% | $247M+57.5% | $156.8M+191% | $53.9M— | |
| CASGEVY | $42.9M-21.0% | $54.3M+221% | $16.9M-44.4% | $30.4M+114% | $14.2M+77.5% | |
| JOURNAVX | $29M+8.6% | $26.7M+36.2% | $19.6M+63.3% | $12M+823% | $1.3M— | |
| Other CF product revenues | $135.9M-42.8% | $237.4M+35.0% | $175.8M-25.5% | $236.1M+52.0% | $155.3M-18.8% | |
| TRIKAFTA/KAFTRIO | $2.35B-8.5% | $2.57B-3.1% | $2.65B+4.0% | $2.55B+0.6% | $2.54B-6.8% | |
| Product revenues, net by Geography | ||||||
| Europe | $950M— | —— | —— | —— | $826.6M-0.6% | |
| Other | $261M— | —— | —— | —— | $280.1M+27.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vertex Pharmaceuticals break its business down?
- Vertex Pharmaceuticals (VRTX) reports product revenues, net by product across 5 parts — ALYFTREK, CASGEVY, JOURNAVX, Other CF product revenues and TRIKAFTA/KAFTRIO. Each is extracted from the segment footnotes and tracked over time.
- Where does Vertex Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vertex Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
